Based on the presence of somatic mutations in TP53 and FGFR3, we divided the BLCA cohort into three groups: TP53-mutant, FGFR3-mutant, and no TP53 and FGFR3-mutant. This evidence concerns the gene FGFR3 and bladder transitional cell carcinoma.